BASF acquisition a positive for Amarin, says Leerink Leerink views BASF's (BASFY) acquisition of Pronova BioPharma a positive for Amarin (AMRN). The firm believes the deal sets a high floor value for Amarin's Vascepa and reiterates an Outperform rating on the stock with a $27 fair value estimate.
BASF added to Best of Bernstein list at Bernstein Bernstein believes that the decline of BASF's stock has created a buying opportunity, as the firm thinks that the company's fundamentals remain strong. Bernstein predicts that the company will generate 6% EBIT growth this year, beating the consensus outlook and its guidance. It keeps an Outperform rating on the shares.